Alzheimer's disease drug development pipeline: 2023
Alzheimer's disease drug development pipeline: 2023
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed.
Methods
We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD. We created an automated computational database...
Alternative Titles
Full title
Alzheimer's disease drug development pipeline: 2023
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ecd89b237a8d4c8382a46b97170815de
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ecd89b237a8d4c8382a46b97170815de
Other Identifiers
ISSN
2352-8737
E-ISSN
2352-8737
DOI
10.1002/trc2.12385
